FDA.reportPublic FDA data

lanadelumab-flyo 300 MG per 2 ML Injection

RxCUI
2055645
RxNorm name
lanadelumab-flyo 300 MG per 2 ML Injection
Display name
lanadelumab-flyo 300 MG per 2 ML Injection
Full name
lanadelumab-flyo 300 MG per 2 ML Injection
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:38:48

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761090Takhzyrolanadelumab-flyo351(a)Disc2026-09-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
15f99d8c-efe7-4f7d-aa20-0d0f1e30c6e8lanadelumab-flyo 300 MG in 2 ML Injection [PSN] · 2 ML lanadelumab-flyo 150 MG/ML Injection [SCD] · lanadelumab-flyo 300 MG per 2 ML Injection [SY]314These highlights do not include all the information needed to use TAKHZYRO ® safely and effectively. See full prescribing information for TAKHZYRO ® . TAKHZYRO ® (lanadelumab-flyo) injection, for subcutaneous use Initial U.S. Approval: 201820250228